23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

23andMe is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing business. A special committee of its directors’ board is considering ...

23andMe is in need of cash and weighing a sale of the company. The DNA-testing company said Tuesday that it is exploring strategic alternatives, including a business combination and the sale of ...

Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company, after months of speculation about its future. The company's board has formed a ...

SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help ...

23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...

SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today announced the launch of Discover23®, a new research ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year ...

23andMe faced major hurdles in 2024, including a $30 million settlement related to compromised data. 23andMe is now restructuring its business operations to reduce costs and streamline operations. A ...